We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Lonza Introduces Fresh Human Pancreatic Islets
Product News

Lonza Introduces Fresh Human Pancreatic Islets

Lonza Introduces Fresh Human Pancreatic Islets
Product News

Lonza Introduces Fresh Human Pancreatic Islets


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Lonza Introduces Fresh Human Pancreatic Islets"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Lonza has announced the launch of new Clonetics™ Fresh Human Pancreatic Islets. Lonza's pancreatic islets possess a guaranteed quality with each batch tested for quantity (total IEQ), viability, purity, and sterility.

They can be used in a variety of research areas including islet cell transplantation, insulin production, cell metabolism, immunosuppression, and other metabolic disorders.

Some of the major challenges within the diabetes research are the acquisition and availability of high-quality islet cells.

Researchers will now have easy access to islets to support research in long-term islet grafting survival, prevention of islet rejection, and prevention of adverse effects from immunosuppressive drugs.

The Global Head of Marketing Lonza Bioscience Research and Testing Products, Claus-Dietmar Pein states, "It is exciting to be able to offer these cells to the commercial research market due to high market interest and limited accessibility to date. This is a nice extension to our existing metabolic disease product portfolio to further advance research and drug discovery in this area."

Allowing researchers to avoid roadblocks in Diabetes Research, the new offering enhances the comprehensive collection of Lonza's metabolic research-based products and services.

Advertisement